Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part III – analytical issues. Issue 5 (10th September 2013)

• Record Type: Journal Article
• Authors: Tanqri, Shabnam; Vall, Horacio; Kaplan, David; Hoffman, Bob; Purvis, Norman; Porwit, Anna; Hunsberger, Ben; Shankey, T. Vincent; Béné, Marie C.; Marti, Gerald E.
• Is Part Of: Cytometry. Volume 84:Issue 5(2013)
• Page Start: 291
• Page End: 308
• Publication Date: 2013-09-10
• Subjects: Flow cytometry -- Diagnostic use -- Periodicals; Cytodiagnosis -- Periodicals; 616.07582
• DOI: 10.1002/cyto.b.21106
• Languages: English
• ISSNs: 1552-4949

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Clinical diagnostic assays, may be classified as quantitative, quasi‐quantitative or qualitative. The assay's description should state what the assay needs to accomplish (intended use or purpose) and what it is not intended to achieve. The type(s) of samples (whole blood, peripheral blood mononuclear cells (PBMC), bone marrow, bone marrow mononuclear cells (BMMC), tissue, fine needle aspirate, fluid, etc.), instrument platform for use and anticoagulant restrictions should be fully validated for stability requirements and specified. When applicable, assay sensitivity and specificity should be fully validated and reported; these performance criteria will dictate the number and complexity of specimen samples required for validation. Assay processing and staining conditions (lyse/wash/fix/perm, stain pre or post, time and temperature, sample stability, etc.) should be described in detail and fully validated. © 2013 International Clinical Cytometry Society</p> </abstract>